Here are 1-2 brief analogies for Zevra Therapeutics:

• Zevra Therapeutics is like the Dolby Labs of pharmaceuticals, specializing in a unique 'prodrug' technology that enhances existing medications to make them safer or more effective.
• Zevra Therapeutics is like the AMG (Mercedes-AMG) for pharmaceuticals, taking existing, proven drugs and re-engineering them with proprietary 'prodrug' technology to create enhanced, specialized versions with improved profiles.

```html

• KP1077: A prodrug of d-methylphenidate in Phase II clinical trials for idiopathic hypersomnia (IH) and narcolepsy.
• KP879: A prodrug product candidate in Phase I clinical trials for the treatment of stimulant use disorder.
• AZSTARYS: An FDA-approved, once-daily treatment for attention deficit hyperactivity disorder (ADHD) in patients aged six years and older.
• APADAZ: An immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen.

```

Zevra Therapeutics (ZVRA) sells primarily to other companies. Its major customers are entities with whom it enters into collaboration and license agreements for its developed pharmaceutical products.

• KVK-Tech, Inc.
• Commave Therapeutics SA

null

Neil F. McFarlane, President & Chief Executive Officer Mr. McFarlane has served as Zevra's President, Chief Executive Officer, and a director of the Company since October 2023. He brings over 25 years of global biopharmaceutical and life sciences experience. Prior to Zevra, he was a board member at Collegium Pharmaceutical Inc. from April 2022 to July 2024. Mr. McFarlane also served as the Chief Executive Officer and a member of the board of directors of Adamas Pharmaceuticals, Inc. from September 2019 until its acquisition by Supernus Pharmaceuticals, Inc. in November 2021. His past experience also includes roles as Chief Operating Officer at Travere Therapeutics (formerly Retrophin, Inc.), and various leadership positions at UCB, Genzyme Corporation (now Sanofi), and Sangstat Medical Corporation. Justin Renz, Chief Financial Officer Mr. Renz was appointed as Chief Financial Officer, effective March 9, 2026, bringing over 25 years of financial leadership experience in the biopharmaceutical industry. His expertise spans capital markets, strategic transactions, and commercial-stage operations. Most recently, Mr. Renz served as Chief Financial & Operations Officer at Ardelyx, where he played an active role in the launch and commercialization of two innovative medicines. He previously held the positions of President and Chief Financial Officer of Correvio Pharma, Executive Vice President, Chief Financial Officer and Treasurer at Karyopharm Pharmaceuticals, and Executive Vice President and Chief Financial Officer at Zalicus Inc. Joshua Schafer, Chief Commercial Officer Mr. Schafer has served as Zevra's Chief Commercial Officer since January 2023, and also as Executive Vice President, Business Development from January 2023 to March 2025. He possesses over 25 years of experience in pharmaceutical commercial, new product development, and merger and acquisition (M&A) activities. Previously, Mr. Schafer served as General Manager of the Autoimmune and Rare Disease business at Mallinckrodt Pharmaceuticals, and before that, as Chief Strategy and Business Officer. Adrian Quartel, M.D., FFPM, Chief Medical Officer Dr. Quartel serves as Zevra's Chief Medical Officer. Rahsaan W. Thompson, Chief Legal Officer, Secretary and Compliance Officer Mr. Thompson was appointed as Chief Legal Officer, Secretary and Compliance Officer in June 2024. He brings more than 25 years of experience as a business leader and attorney in the biotech industry. Prior to joining Zevra, Mr. Thompson was the Chief Legal Officer at Lyell Immunopharma, a publicly traded, clinical-stage biotech corporation. His extensive background includes corporate governance, clinical studies, intellectual property, licensing arrangements, and litigation.

Zevra Therapeutics (NASDAQ: ZVRA) faces several key risks to its business, primarily stemming from its reliance on a single product for revenue, the inherent uncertainties of drug development, and underlying financial stability concerns. The most significant risk is the **dependence on MIPLYFFA** for a substantial portion of its revenue. MIPLYFFA (arimoclomol), approved for Niemann-Pick disease type C, accounted for 77.4% of Zevra's fourth-quarter 2025 revenue and $87.4 million of its $106.5 million full-year 2025 net revenue. This product concentration means that any challenges to MIPLYFFA's market uptake, competition from emerging treatments, or regulatory hurdles for expanding its market authorization in regions like Europe could significantly impact the company's financial performance. A second key risk involves the **clinical trial and regulatory approval process for its pipeline candidates**. While Zevra has approved products, its future growth and diversification rely on the successful development and commercialization of investigational therapies such as KP1077 (for idiopathic hypersomnia and narcolepsy) and celiprolol (for Vascular Ehlers-Danlos Syndrome). "Hiccups in late-stage trials for KP1077 or Celiprolol could challenge the thesis" of the company's future prospects. Drug development is a complex and high-risk endeavor, with no guarantee of successful trial outcomes or regulatory approvals. Finally, Zevra Therapeutics faces **financial stability concerns**, despite reporting a swing to profitability in 2025, aided by a significant gain from the sale of a priority review voucher. The company's financial health indicators, such as a Z-Score in the "grey area" and a Beneish M-Score suggesting possible financial manipulation, point to potential underlying financial stress. Furthermore, Zevra recognized a $58.7 million impairment charge related to definite-lived intangible assets in the quarter ending June 30, 2025, highlighting the risk of future impairments that could adversely affect its operating results and financial stability.

null

```html ```

Zevra Therapeutics (NASDAQ: ZVRA) is strategically positioned for future revenue growth over the next 2-3 years, primarily by focusing on its rare disease product portfolio and pipeline advancements. Here are 4 expected drivers of future revenue growth: * **Expanded commercialization of MIPLYFFA (arimoclomol) in the U.S. for Niemann-Pick disease type C (NPC):** MIPLYFFA received U.S. FDA approval in September 2024 and has demonstrated strong commercial uptake, serving as a primary revenue driver for the company in 2025. Zevra is actively engaged in initiatives to increase patient enrollment, improve payer coverage (aiming for 78-79% from the current 52%), and enhance diagnostic efforts to identify more of the estimated 900 individuals living with NPC in the U.S.. * **European expansion of MIPLYFFA:** Zevra has submitted a Marketing Authorization Application (MAA) for MIPLYFFA to the European Medicines Agency (EMA) in July 2025, which is currently under review. A successful approval and subsequent commercial launch in Europe would open a significant new market, driving substantial revenue growth through geographic expansion. The company is evaluating pricing strategies and potential partnership options for this expansion. * **Advancement of KP1077 for Idiopathic Hypersomnia (IH) and Narcolepsy into pivotal Phase 3 trials:** KP1077, targeting rare sleep disorders, has shown promising top-line Phase 2 data for idiopathic hypersomnia, indicating clinically meaningful improvements in excessive daytime sleepiness and good tolerability. Zevra plans to engage with the U.S. FDA to discuss the design of a pivotal Phase 3 clinical trial. Progressing KP1077 through late-stage clinical development and towards a potential launch within the 2-3 year timeframe is a key pipeline driver for future revenue. * **Increased commercialization and market penetration of OLPRUVA for Urea Cycle Disorders (UCDs):** Zevra launched OLPRUVA in early 2024 following the acquisition of Acer Therapeutics in November 2023. Despite initial slower patient enrollment, the company is focused on highlighting OLPRUVA's clinical advantages and improving market dynamics to drive its commercial growth. Continued efforts to enhance patient access and reimbursement support are expected to increase its revenue contribution.

Share Issuance

• Zevra Therapeutics' common shares outstanding increased from 53.67 million at the end of fiscal year 2024 to 56.30 million as of March 2026, indicating share issuances during this period.

Inbound Investments

• Zevra Therapeutics issued long-term debt totaling $58.99 million in fiscal year 2024, $42.43 million in fiscal year 2023, and $12.8 million in fiscal year 2022.
• The company announced a plan to sell a Priority-Review Voucher for $150 million in February 2025.

Outbound Investments

• In May 2022, Zevra Therapeutics, then known as KemPharm, acquired arimoclomol from Orphazyme A/S as part of its strategy to focus on rare diseases.
• The company made payments for business acquisitions of $30.4 million in fiscal year 2023 and $14.09 million in fiscal year 2022.

Capital Expenditures

• Zevra Therapeutics' capital expenditures were $0.31 million for the trailing twelve months ending June 2025, and $0.3 million in fiscal year 2023, with no capital expenditures reported in fiscal year 2024.